Zacks Investment Research on MSN
Merck's ADC candidate meets goals in endometrial cancer study
Merck MRK announced that the pivotal phase III TroFuse-005 study, which evaluated its pipeline candidate, sacituzumab ...
The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...
Merck's TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints of OS and PFS in Certain Patients With Advanced or ...
The TROP2-directed antibody-drug conjugate demonstrated superior efficacy over physician’s choice of chemotherapy in patients previously treated with platinum-based therapy and immunotherapy.
Clinical Trials Arena on MSN
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial
MSD’s sac-TMT is being developed in collaboration with Kelun-Biotech in a range of cancer indications.
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...
Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...
Drs Ursula A. Matulonis and Kathleen N. Moore discuss the different aspects of ADCs in endometrial cancer, medications that are currently available, and promising HER2 ADCs. Drs Ursula A. Matulonis ...
Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and treat ER+ metastatic endometrial cancer. Drs Ursula A. Matulonis and ...
What Is Metastatic Endometrial Cancer? Metastatic endometrial cancer is when cancer that starts in the lining of the uterus (endometrium) spreads to other parts of the body. Your doctor may call it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results